Top

Cancer Cell International

Published in:

01-12-2021 | Metastasis | Primary research

EZR promotes pancreatic cancer proliferation and metastasis by activating FAK/AKT signaling pathway

Authors: Jian Xu, Wei Zhang

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

As a member of the ERM (ezrin-radixin-moesin) protein family, EZR has been recognized as a regulator of adhesion signal pathways by researchers. Moreover, EZR was thought to play irreplaceable roles in invasion and metastasis of versatile cancers. In this study, we managed to undermine the effect of EZR on proliferation and metastasis in pancreatic cancer (PC).

Methods

To analyze the impact of EZR expression on overall survival and free diseases survival of PC patients, we screened abnormally expressed EZR in PC using the Gene Expression Omnibus database (GEO database) and The Cancer Genome Atlas (TCGA) database. Following, Gene Ontology (GO)-based functional analysis and Gene set enrichment analysis (GSEA) was performed to predicate the possible biological processes in which EZR were involved. The clinicopathological characteristics and prognosis of PC patients were analyzed according to clinical data. Further, immunohistochemistry, western blotting and real time PCR analysis were conducted to analyze the expression level of EZR in PC and paired paracancerous tissues. The effect of EZR on proliferation of PC cell lines were detected by Cell Counting Kit-8 assay, and meanwhile, Transwell assay was performed to detect the effect of EZR on invasion and migration of PC cell.

Result

EZR exhibited higher expression level in pancreatic cancer tissues and cell than paracancerous tissues and cell, and its expression level was positively correlated with poor overall survival and diseases-free survival in PC patients. CCK8 assay indicated that EZR facilitated the proliferation of PC cells, meanwhile, Transwell assay showed that EZR promoted the migration and invasion of PC cells. The GO analysis predicated that EZR was involved in biological processes including cell adhesion, ameboidal-type cell migration, cell junction assembly. Through GSEA analysis, pancreatic cancer pathway, and the adhesion junction pathway were screened as the mostly enriched pathways in EZR-regulated pathological process. The inhibition of EZR suppressed proliferation and migration of PC cells. Western blot experiment revealed a positive correlation between EZR and FAK, the proliferation invasion and migration ability of PC cells were significantly decreased after knockdown of EZR.

Conclusion

Our finding revealed EZR accelerated the progression of PC via FAK/AKT signaling pathway.

Available only for authorised users

Versteijne E, Suker M, Groen J, Besselink M, Bonsing B, Bosscha K, Busch O, de Hingh I, De Jong K, Molenaar I, van Santvoort H, Verkooijen H, Van Eijck C, et al. External validity of the multicenter randomized PREOPANC trial on neoadjuvant chemoradiotherapy in pancreatic cancer: outcome of eligible but non-randomized patients. Ann Surg. 2020. https://doi.org/10.1097/SLA.0000000000004364.CrossRefPubMed

Wang J, Zhu Y, Chen J, Yang Y, Zhu L, Zhao J, Yang Y, Cai X, Hu C, Rosell R, Sun X, Cao P. Identification of a novel PAK1 inhibitor to treat pancreatic cancer. Acta Pharmaceutica Sinica B. 2020;10(4):603–14.PubMedCrossRef

Kibe S, Ohuchida K, Ando Y, Takesue S, Nakayama H, Abe T, Endo S, Koikawa K, Okumura T, Iwamoto C, Shindo K, Moriyama T, Nakata K, et al. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Cancer Lett. 2019;444:70–81.PubMedCrossRef

Dalgleish A, Stebbing J, Adamson D, Arif S, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, et al. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer. 2016;115(7):789–96.PubMedPubMedCentralCrossRef

Aung K, Fischer S, Denroche R, Jang G, Dodd A, Creighton S, Southwood B, Liang S, Chadwick D, Zhang A, O’Kane G, Albaba H, Moura S, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344–54.PubMedCrossRef

Tanaka M, Okazaki T, Suzuki H, Abbruzzese J, Li D. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer. 2011;117(4):744–51.PubMedCrossRef

Amponsah P, Fan P, Bauer N, Zhao Z, Gladkich J, Fellenberg J, Herr I. microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. Cancer Lett. 2017;388:107–17.PubMedCrossRef

Jin G, Hong W, Guo Y, Bai Y, Chen B. Molecular mechanism of pancreatic stellate cells activation in chronic pancreatitis and pancreatic cancer. J Cancer. 2020;11(6):1505–15.PubMedPubMedCentralCrossRef

Du Y, Liu Z, You L, Wu W, Zhao Y. Advances in understanding the molecular mechanism of pancreatic cancer metastasis. Hepatobiliary Pancreat Dis Int. 2016;15(4):361–70.PubMedCrossRef

10.

Xiao Z, Luo G, Liu C, Wu C, Liu L, Liu Z, Ni Q, Long J, Yu X. Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed Res Int. 2014;2014: 925845.PubMedPubMedCentral

11.

Hunter K. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004;10(5):201–4.PubMedCrossRef

12.

Pomaznoy M, Ha B, Peters B. GOnet: a tool for interactive gene ontology analysis. BMC Bioinform. 2018;19(1):470.CrossRef

13.

Ardura J, Wang B, Watkins S, Vilardaga J, Friedman P. Dynamic Na+-H+ exchanger regulatory factor-1 association and dissociation regulate parathyroid hormone receptor trafficking at membrane microdomains. J Biol Chem. 2011;286(40):35020–9.PubMedPubMedCentralCrossRef

14.

Bulut G, Hong S, Chen K, Beauchamp E, Rahim S, Kosturko G, Glasgow E, Dakshanamurthy S, Lee H, Daar I, Toretsky J, Khanna C, Uren A. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 2012;31(3):269–81.PubMedCrossRef

15.

Pei Y, Yao Q, Li Y, Zhang X, Xie B. microRNA-211 regulates cell proliferation, apoptosis and migration/invasion in human osteosarcoma via targeting EZRIN. Cell Mol Biol Lett. 2019;24:48.PubMedPubMedCentralCrossRef

16.

Chiappetta C, Leopizzi M, Censi F, Puggioni C, Petrozza V, Rocca C, Di Cristofano C. Correlation of the Rac1/RhoA pathway with ezrin expression in osteosarcoma. Appl Immunohistochem Mol Morphol. 2014;22(3):162–70.PubMedCrossRef

17.

Li N, Kong J, Lin Z, Yang Y, Jin T, Xu M, Sun J, Chen L. Ezrin promotes breast cancer progression by modulating AKT signals. Br J Cancer. 2019;120(7):703–13.PubMedPubMedCentralCrossRef

18.

Zhang R, Zhang S, Xing R, Zhang Q. High expression of EZR (ezrin) gene is correlated with the poor overall survival of breast cancer patients. Thorac Cancer. 2019;10(10):1953–61.PubMedPubMedCentralCrossRef

19.

Tanaka T, Bai Z, Srinoulprasert Y, Yang B, Yang B, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci. 2005;96(6):317–22.PubMedCrossRef

20.

Yang J, Zhu D, Zhou X, Yin N, Zhang Y, Zhang Z, Li D, Zhou J. HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter. Oncotarget. 2017;8(29):47801–15.PubMedPubMedCentralCrossRef

21.

Feng L, Wang K, Tang P, Chen S, Liu T, Lei J, Yuan R, Hu Z, Li W, Yu X. Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis. Aging. 2020;12(19):19273–92.PubMedPubMedCentralCrossRef

22.

Jing Y, Liang W, Liu J, Zhang L, Wei J, Zhu Y, Yang J, Ji K, Zhang Y, Huang Z. Stress-induced phosphoprotein 1 promotes pancreatic cancer progression through activation of the FAK/AKT/MMP signaling axis. Pathology. 2019;215(11): 152564.

23.

Zhu X, Wang J, Li L, Deng L, Wang J, Liu L, Zeng R, Wang Q, Zheng Y. GPX3 suppresses tumor migration and invasion via the FAK/AKT pathway in esophageal squamous cell carcinoma. Am J Transl Res. 2018;10(6):1908–20.PubMedPubMedCentral

24.

McGuigan A, Kelly P, Turkington R, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–61.PubMedPubMedCentralCrossRef

25.

Nattress C, Halldén G. Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Lett. 2018;434:56–69.PubMedCrossRef

26.

Park S, Oh C, Kim M, Ha E, Choi Y, Ryoo J. Metabolic syndrome, metabolic components, and their relation to the risk of pancreatic cancer. Cancer. 2020;126(9):1979–86.PubMedCrossRef

27.

Daoud A, Mulholland E, Cole G, McCarthy HO. MicroRNAs in pancreatic cancer: biomarkers, prognostic, and therapeutic modulators. BMC Cancer. 2019;19(1):1130.PubMedPubMedCentralCrossRef

28.

Eissa M, Lerner L, Abdelfatah E, Shankar N, Canner J, Hasan N, Yaghoobi V, Huang B, Kerner Z, Takaesu F, Wolfgang C, Kwak R, Ruiz M, et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenet. 2019;11(1):59.CrossRef

29.

Tsiaousidou A, Lambropoulou M, Chatzitheoklitos E, Tripsianis G, Tsompanidou C, Simopoulos C, Tsaroucha AK. B7H4, HSP27 and DJ-1 molecular markers as prognostic factors in pancreatic cancer. Pancreatology. 2013;13(6):564–9.PubMedCrossRef

30.

Zhang X, Huang G, Xie Y, He J, Guo J, Xu X, Liao L, Xie Y, Song Y, Li E, Xu L. The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells. Nucleic Acids Res. 2018;46(4):1793–809.PubMedCrossRef

31.

Zhu Y, Zhu M, Zhang X, Xu X, Wu Z, Liao L, Li L, Xie Y, Wu J, Zou H, Xie J, Li E, Xu L. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. Hum Pathol. 2016;52:153–63.PubMedCrossRef

32.

Zhu L, Ito T, Nakahara T, Nagae K, Fuyuno Y, Nakao M, Akahoshi M, Nakagawa R, Tu Y, Uchi H, Furue M. Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma. J Dermatol. 2013;40(12):973–9.PubMedCrossRef

33.

Horwitz V, Davidson B, Stern D, Tropé C, Tavor Re’em T, Reich R. Ezrin is associated with disease progression in ovarian carcinoma. PLoS ONE. 2016;11(9): e0162502.PubMedPubMedCentralCrossRef

34.

Ghaffari A, Hoskin V, Turashvili G, Varma S, Mewburn J, Mullins G, Greer P, Kiefer F, Day A, Madarnas Y, SenGupta S, Elliott BE. Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer. Breast Cancer Res. 2019;21(1):12.PubMedPubMedCentralCrossRef

35.

Carneiro A, Bendahl P, Åkerman M, Domanski H, Rydholm A, Engellau J, Nilbert M. Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. J Clin Pathol. 2011;64(8):689–94.PubMedCrossRef

36.

Zacapala-Gómez A, Navarro-Tito N, Alarcón-Romero L, Ortuño-Pineda C, Illades-Aguiar B, Castañeda-Saucedo E, Ortiz-Ortiz J, Garibay-Cerdenares O, Jiménez-López M, Mendoza-Catalán MA. Ezrin and E-cadherin expression profile in cervical cytology: a prognostic marker for tumor progression in cervical cancer. BMC Cancer. 2018;18(1):349.PubMedPubMedCentralCrossRef

37.

Sarrió D, Rodríguez-Pinilla S, Dotor A, Calero F, Hardisson D, Palacios J. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat. 2006;98(1):71–9.PubMedCrossRef

38.

Ma L, Liu Y, Zhang X, Geng C, Li Z. Relationship of RhoA signaling activity with ezrin expression and its significance in the prognosis for breast cancer patients. Chin Med J. 2013;126(2):242–7.PubMed

39.

Lugowska I, Mierzejewska E, Lenarcik M, Klepacka T, Koch I, Michalak E, Szamotulska K. The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults. Tumour Biol. 2016;37(9):12071–8.PubMedCrossRef

40.

Chang Y, Peng H, Hu C, Huang S, Tien S, Jeng Y. Pancreatic cancer-derived small extracellular vesical Ezrin regulates macrophage polarization and promotes metastasis. Am J Cancer Res. 2020;10(1):12–37.PubMedPubMedCentral

41.

Zhang X, Ruan Q, Zhai Y, Lu D, Li C, Fu Y, Zheng Z, Song Y, Guo J. Baicalein inhibits non-small-cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment. Cancer Sci. 2020;111(10):3802–12.PubMedPubMedCentralCrossRef

42.

Pan D, Wang S, Ye H, Xu S, Ye G. Ezrin expression in the primary hepatocellular carcinoma patients and associated with clinical, pathological characteristics. J Cancer Res Ther. 2016;12:C291–4.PubMedCrossRef

43.

Wang X, Li N, Han A, Wang Y, Lin Z, Yang Y. Ezrin promotes hepatocellular carcinoma progression by modulating glycolytic reprogramming. Cancer Sci. 2020;111(11):4061–74.PubMedPubMedCentralCrossRef

Title: EZR promotes pancreatic cancer proliferation and metastasis by activating FAK/AKT signaling pathway
Authors: Jian Xu
Wei Zhang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Pancreatic Cancer
Pancreatic Cancer
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02222-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

GNRH1 and LTB4R might be novel immune-related prognostic biomarkers in clear cell renal cell carcinoma (ccRCC)

The biological function and clinical significance of STIL in osteosarcoma

Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?

CircTUBGCP3 facilitates the tumorigenesis of lung adenocarcinoma by sponging miR-885-3p

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients

NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer